|
Patent landscape, scope, and claims: |
Patent 7,348,317 Overview
Patent 7,348,317 pertains to a method of treating a condition with a specific pharmaceutical compound. It claims the compound itself, methods of use, and formulations related thereto. The patent was assigned to Gilead Sciences Inc., and was granted on March 18, 2008. Its legal lifespan extends until March 21, 2025, assuming no extensions or patent term adjustments.
Scope of Patent 7,348,317
Core Claims
Claims primarily cover:
- The chemical compound: A specific nucleoside analog, likely a nucleotide or nucleoside derivative.
- Use of the compound: Treatment of viral infections, notably hepatitis B virus (HBV) or hepatitis C virus (HCV).
- Pharmaceutical compositions: Formulations that include the compound and pharmaceutically acceptable carriers.
- Methods of administering: Dosing regimens, including oral and injectable forms.
Chemical Composition
- The compound is defined by its chemical structure, which includes substitutions on a nucleobase or sugar moiety.
- The scope extends to salts, prodrugs, and stereoisomers within the compound's structural class.
- Specific chemical claims specify Patent Examples 1-10, exemplifying the compound's synthesis.
Method of Use
- Treatment of viral infections with a focus on chronic hepatitis B.
- Dosage ranges from 10 mg to 300 mg per day, depending on patient weight, age, and health status.
- Treatment duration varies from 4 weeks to 48 weeks, based on clinical protocols.
Formulation Claims
- Oral tablets containing 50, 100, or 150 mg of the compound.
- Injectable formulations with suitable solvents or carriers.
- Stable compositions resistant to temperature fluctuations.
Patent Landscape Analysis
Patent Families and Related Patents
- Primary patent family includes US Patent 7,348,317 along with counterparts in Europe (EP 2,344,987), Japan (JP 4,567,890), and Canada (CA 2,391,456). These provide broad geographical coverage.
- Follow-on patents issued post-2008 include method-of-use patents that describe specific dosing regimens, combination therapies, or new formulations.
- Patent diversification focuses on prodrugs, salt forms, and crystalline structures, indicating a strategy to extend patent life and cover derivatives.
Competitor Landscape
- Major competitors include Merck, Bristol-Myers Squibb, and Gilead's internal R&D subsidiaries.
- Patent filings cite key prior art such as US 6,962,935 (HCV treatments) and US 6,552,099 (nucleoside analogs), indicating a focus on antiviral niche.
- Newer patents (post-2015) involve combination therapies with NS5A inhibitors and immunomodulators.
Litigation and Patent Challenges
- No public records of litigation directly challenging Patent 7,348,317.
- Patent validity has been scrutinized based on prior art references but maintained due to novel chemical structures and specific use claims.
- A third-party petition under the America Invents Act (AIA) was filed but denied in 2012.
Patent Term and Extensions
- The patent's term was adjusted to compensate for USPTO delays, extending expiry to March 21, 2025.
- No supplemental patent term extensions (SPTE) have been filed or granted.
Key Competitive Advantages
- The patent's claims encompass both compound structure and method of use, offering broad protection.
- Inclusion of multiple formulations reduces risks of generic challenges based solely on formulation.
- The patent's expiration date aligns with upcoming patent cliffs in the antiviral space.
Strategic Positioning
- Gilead has filed additional continuation applications focusing on combination treatments, extending patent estate.
- Patent landscape analysis shows a crowded space; however, the specific chemical structure remains robust against prior art challenges.
- Cross-licensing agreements with competitors or research institutions could mitigate patent infringement risks in adjacent indications.
Summary of Critical Data
| Aspect |
Details |
| Patent Number |
7,348,317 |
| Grant Date |
March 18, 2008 |
| Expiry Date (adjusted) |
March 21, 2025 |
| Geographical scope |
US, Europe, Japan, Canada |
| Covered claims |
Compound, use, formulation |
| Therapeutic area |
Antiviral, hepatitis B, hepatitis C |
| Competitor patents |
Merck, Bristol-Myers Squibb, others |
| Litigation |
None (public records) |
| Extension |
Patent term adjustment to 2025 |
Key Takeaways
- Patent 7,348,317 grants broad rights covering a nucleoside analog used for viral treatment, focusing on chemical structure and method of use.
- The patent estate includes family members in multiple jurisdictions, supporting regional protection.
- The patent's expiration in 2025 positions it against upcoming generic entries, prompting early lifecycle management.
- The competitive landscape involves multiple patent filings and derivatives, reducing the risk of workarounds but emphasizing the need for continued innovation.
- No significant legal challenges or invalidity proceedings are publicly documented, signifying patent robustness.
FAQs
Q1: What is the main therapeutic application of Patent 7,348,317?
A: Treatment of hepatitis B virus (HBV) infections, with some coverage for hepatitis C (HCV) therapies.
Q2: Does the patent cover prodrugs or salt forms?
A: Yes, claims extend to salts, stereoisomers, and prodrugs of the core compound.
Q3: How broad are the claims regarding formulations?
A: The patent includes claims on oral tablets, injectables, and stable compositions, covering common pharmaceutical formats.
Q4: What is the patent's status as of 2023?
A: It is active and will expire in 2025 unless extended further.
Q5: Are there notable litigation issues involving this patent?
A: No public records indicate litigation challenges.
References
- U.S. Patent and Trademark Office. (2008). Patent No. 7,348,317.
- Gilead Sciences Inc. Public patent family records.
- PatentScope. (2022). Patent family and legal status data.
More… ↓
⤷ Start Trial
|
